Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: A national survey

Martha S. Kingman, Mark A. Tankersley, Sandra Lombardi, Susan Spence, Fernando Torres, Kelly S. Chin

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: Epoprostenol and treprostinil are intravenous prostacyclin medications used to treat pulmonary arterial hypertension (PAH). This survey explored hospital policies regarding prostacyclin infusions, and investigated the type and frequency of errors that occurred in the inpatient setting. Methods: Information on prostacyclin infusion policies and inpatient errors was obtained through detailed interviews with 18 PAH nurses, and through an electronic survey completed by 97 PAH clinicians. Results: The electronic survey respondents reported wide variability in prostacyclin infusion policies, including variability in the use of home vs hospital infusion pumps, and variability in the use and storage of back-up epoprostenol and treprostinil. Serious or potentially serious errors in medication administration were reported by 68% of survey respondents. The most common error types (reported by <25%), included: incorrect cassette placed in the pump; inaccurate pump programming; errant drug dosing; and inadvertent cessation of the pump. Nine errors, all at different centers, were believed to have contributed to patient death. In the separate interviews with the PAH nurses, 94% reported serious errors. These errors prompted many of the centers to implement policy changes in an attempt to reduce future errors, improve safety and optimize patient outcomes. Conclusions: These findings suggest that prostacyclin infusion therapy is problematic and that an opportunity exists to improve safety. The development of standardized treatment guidelines should be considered.

Original languageEnglish (US)
Pages (from-to)841-846
Number of pages6
JournalJournal of Heart and Lung Transplantation
Volume29
Issue number8
DOIs
StatePublished - 2010

Fingerprint

Epoprostenol
Pulmonary Hypertension
Inpatients
Nurses
Interviews
Infusion Pumps
Medication Errors
Patient Safety
Surveys and Questionnaires
Guidelines
Safety
Therapeutics
Pharmaceutical Preparations

Keywords

  • epoprostenol
  • prostacyclin
  • pulmonary arterial hypertension
  • pulmonary hypertension
  • treprostinil

ASJC Scopus subject areas

  • Transplantation
  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine
  • Surgery

Cite this

Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States : A national survey. / Kingman, Martha S.; Tankersley, Mark A.; Lombardi, Sandra; Spence, Susan; Torres, Fernando; Chin, Kelly S.

In: Journal of Heart and Lung Transplantation, Vol. 29, No. 8, 2010, p. 841-846.

Research output: Contribution to journalArticle

@article{e441c291c9424bf8b98ee83b581b4feb,
title = "Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: A national survey",
abstract = "Background: Epoprostenol and treprostinil are intravenous prostacyclin medications used to treat pulmonary arterial hypertension (PAH). This survey explored hospital policies regarding prostacyclin infusions, and investigated the type and frequency of errors that occurred in the inpatient setting. Methods: Information on prostacyclin infusion policies and inpatient errors was obtained through detailed interviews with 18 PAH nurses, and through an electronic survey completed by 97 PAH clinicians. Results: The electronic survey respondents reported wide variability in prostacyclin infusion policies, including variability in the use of home vs hospital infusion pumps, and variability in the use and storage of back-up epoprostenol and treprostinil. Serious or potentially serious errors in medication administration were reported by 68{\%} of survey respondents. The most common error types (reported by <25{\%}), included: incorrect cassette placed in the pump; inaccurate pump programming; errant drug dosing; and inadvertent cessation of the pump. Nine errors, all at different centers, were believed to have contributed to patient death. In the separate interviews with the PAH nurses, 94{\%} reported serious errors. These errors prompted many of the centers to implement policy changes in an attempt to reduce future errors, improve safety and optimize patient outcomes. Conclusions: These findings suggest that prostacyclin infusion therapy is problematic and that an opportunity exists to improve safety. The development of standardized treatment guidelines should be considered.",
keywords = "epoprostenol, prostacyclin, pulmonary arterial hypertension, pulmonary hypertension, treprostinil",
author = "Kingman, {Martha S.} and Tankersley, {Mark A.} and Sandra Lombardi and Susan Spence and Fernando Torres and Chin, {Kelly S.}",
year = "2010",
doi = "10.1016/j.healun.2010.03.008",
language = "English (US)",
volume = "29",
pages = "841--846",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "8",

}

TY - JOUR

T1 - Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States

T2 - A national survey

AU - Kingman, Martha S.

AU - Tankersley, Mark A.

AU - Lombardi, Sandra

AU - Spence, Susan

AU - Torres, Fernando

AU - Chin, Kelly S.

PY - 2010

Y1 - 2010

N2 - Background: Epoprostenol and treprostinil are intravenous prostacyclin medications used to treat pulmonary arterial hypertension (PAH). This survey explored hospital policies regarding prostacyclin infusions, and investigated the type and frequency of errors that occurred in the inpatient setting. Methods: Information on prostacyclin infusion policies and inpatient errors was obtained through detailed interviews with 18 PAH nurses, and through an electronic survey completed by 97 PAH clinicians. Results: The electronic survey respondents reported wide variability in prostacyclin infusion policies, including variability in the use of home vs hospital infusion pumps, and variability in the use and storage of back-up epoprostenol and treprostinil. Serious or potentially serious errors in medication administration were reported by 68% of survey respondents. The most common error types (reported by <25%), included: incorrect cassette placed in the pump; inaccurate pump programming; errant drug dosing; and inadvertent cessation of the pump. Nine errors, all at different centers, were believed to have contributed to patient death. In the separate interviews with the PAH nurses, 94% reported serious errors. These errors prompted many of the centers to implement policy changes in an attempt to reduce future errors, improve safety and optimize patient outcomes. Conclusions: These findings suggest that prostacyclin infusion therapy is problematic and that an opportunity exists to improve safety. The development of standardized treatment guidelines should be considered.

AB - Background: Epoprostenol and treprostinil are intravenous prostacyclin medications used to treat pulmonary arterial hypertension (PAH). This survey explored hospital policies regarding prostacyclin infusions, and investigated the type and frequency of errors that occurred in the inpatient setting. Methods: Information on prostacyclin infusion policies and inpatient errors was obtained through detailed interviews with 18 PAH nurses, and through an electronic survey completed by 97 PAH clinicians. Results: The electronic survey respondents reported wide variability in prostacyclin infusion policies, including variability in the use of home vs hospital infusion pumps, and variability in the use and storage of back-up epoprostenol and treprostinil. Serious or potentially serious errors in medication administration were reported by 68% of survey respondents. The most common error types (reported by <25%), included: incorrect cassette placed in the pump; inaccurate pump programming; errant drug dosing; and inadvertent cessation of the pump. Nine errors, all at different centers, were believed to have contributed to patient death. In the separate interviews with the PAH nurses, 94% reported serious errors. These errors prompted many of the centers to implement policy changes in an attempt to reduce future errors, improve safety and optimize patient outcomes. Conclusions: These findings suggest that prostacyclin infusion therapy is problematic and that an opportunity exists to improve safety. The development of standardized treatment guidelines should be considered.

KW - epoprostenol

KW - prostacyclin

KW - pulmonary arterial hypertension

KW - pulmonary hypertension

KW - treprostinil

UR - http://www.scopus.com/inward/record.url?scp=77955716352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955716352&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2010.03.008

DO - 10.1016/j.healun.2010.03.008

M3 - Article

C2 - 20430649

AN - SCOPUS:77955716352

VL - 29

SP - 841

EP - 846

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 8

ER -